Entering text into the input field will update the search result below

Smith & Nephew cell therapy fails Phase 3

Oct. 13, 2014 7:14 AM ETSmith & Nephew plc (SNN) StockSNN, SNNUFBy: Douglas W. House, SA News Editor
  • Smith & Nephew's (NYSE:SNN) (OTCPK:SNNUF) living cell therapy product candidate, HP802-247, failed to achieve its primary endpoint in a U.S. Phase 3 clinical trial to assess its safety and efficacy as a treatment for patients with venous leg ulcers. The primary endpoint was a statistically significant improvement in healing compared to placebo.
  • The reported results are top-line data. A full analysis will be completed in the next few months to determine what went wrong considering the strongly positive Phase 2a/2b results. A second Phase 3 being conducted in Europe will continue.
  • Hp802-247 is an allogenic living cell bio-formulation of irradiated keratinocytes and fibroblasts in a human fibrin suspension. It is designed to work with the body's own cells to stimulate healing.

Recommended For You

More Trending News

About SNN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SNN--
Smith & Nephew plc